Inhibitors of SPHK1 are used in ongoing clinical trials to sensitize epithelial ovarian and prostate cancer cells to various chemotherapeutic drugs, e.g., gemcitabine (Guillermet-Guibert et al. 2009). Here, SPHK1 is linked to prostate carcinoma.